anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Essential tremor (ET) is a neurological disorder that affects nearly 0.9% of the world's population, including 300,000 people in France alone. Patients who suffer from this condition usually present an upper limb tremor during voluntary motor activities but not at rest. The pharmacological treatments proposed for this condition are only effective in about 50% of patients, and this effectiveness is often only partial or observed at the cost of unacceptable side effects. Since the end of the 1980's, high-frequency deep brain stimulation (DBS) of the ventral-intermediate nuclei of the thalamus (VIM) has been proposed as an effective second-line treatment for severe forms of ET. However, some neuro-stimulated patients experience a recurrence of their tremor and may complain of an increase in pre-existing cerebellar ataxia. The mechanisms underlying these phenomena are still debated, but the fact that VIM stimulation is applied in a chronic and undifferentiated manner seems to play a determining role. One way to circumvent these phenomena could be to stimulate the VIM only during movement since the tremor in this condition is an action or postural tremor. This type of "closed-loop therapy" requires one or more intracerebral tremor biomarkers that can be reliably recognized and used to automatically trigger or modulate the intensity of VIM stimulation only when necessary. In a preliminary study in 10 patients, the investigators of Bordeaux university hospital were able to demonstrate the existence of potential intracerebral biomarkers of tremor under experimental conditions,in the immediate postoperative period (Guehl et al. 2022, submitted). The arrival on the market of the PERCEPT™ (new stimulator/recorder, Medtronic, Minneapolis, USA) now allows, in addition to treating patients with DBS, the recording of intracerebral activity at a distance from surgery, in a non-invasive way and in ecological condition at home. This study aim at recording the variations of thalamic oscillations, in ecological condition, during rest and movement, with and without deep brain stimulation. These measurements will be performed once a week during the 12 weeks of the late post-operative period (from 3 to 6 months), in order to ensure the reproducibility of the results. The signal processing and analysis will be performed in a blind manner to the patient's activity and stimulation condition.
A polyvinylidene fluoride-based composition comprising: 1. 30-60% by weight of total solids selected from the group consisting of polyvinylidine difluoride and copolymers thereof. 2. 10-20% by weight of total solids of a polymer of monomers selected from the group consisting of lower alkylacrylate, a lower alkyl (meth)acrylate, a hydroxy lover alkylacrylate, an alpha beta unsaturated carboxylic acid having an acid number of about 20 to 150, and the copolymers thereof. 3. 30-60% by weight of total solids of a polymer of monomers selected from the group consisting of a dialkylaminoalkyl(meth)acrylate and lower alkyl(meth)acrylate. 4. 0.5-2.0% of water based on total composition weight. 5. An effective amount of an antimicrobial agent. 6. An aqueous organic solvent for dissolving all components. The film is used to form a flexible, tack-free, non-flammable, fluid resistant barrier film with durability and skin-adhesion properties. The composition provides a long-lasting protective barrier film capable of disinfecting the skin surface of normally present micro-organisms upon initial application, and the film imparting continuous and prolonged antimicrobial properties to the skin surface through sustained release of an encapsulated antimicrobial agent. The barrier film is further capable of remaining adherent to the skin surface after exposure to biological fluids.
The project involves the development of a virtual intervention program for targets of peer victimization. Intervention for Victimized Youth (IVY) will improve upon many limitations of existing interventions described above since it is the first intervention program to specifically address the needs of targets of peer victimization from a trauma perspective. Moreover, it addresses key limitations of CBITS and increases the flexibility of the intervention by using a virtual delivery model. Just as ivy plants are strong and can flourish in difficult environments, the goal of IVY is for victimized youth to thrive academically and socially despite challenging circumstances. IVY uses a cognitive behavioral therapy (CBT) approach to address current distress due to peer victimization and teach strategies for handling any future peer victimization. Common elements of effective CBT-based trauma treatments are psychoeducation, emotion regulation skills, imaginal or in vivo exposure, cognitive processing, and/or problem solving. Several methods are used within sessions to teach the content, including psychoeducation, didactic teaching, modeling, role playing, and guided self-reflection.

The proposed 8-week intervention. The focus of the first 4 sessions will be on teaching skills to help students overcome emotional difficulties associated with being victimized. Weekly topics include: 1) Introduction \& Psychoeducation, 2) Emotional Regulation Skill Building and Practice, 3) Identifying \& Coping with Difficult Thoughts and Emotions, and 4) Connecting Thoughts, Emotions, and Behaviors. The last 4 sessions are specific to peer victimization issues with a focus on avoiding re-victimization since victimized youth often are victimized repeatedly and report that they defend other victims. Weekly topics include: 5) Options for Protecting Yourself, 6) Social Problem-Solving Skills, 7) Adaptive Thinking, and 8) Future Planning \& Celebration. Participants will be taught several options for intervening. A decision-making process for evaluating social situations will be taught. Based on the outcome of that decision-making process, participants will be taught options for responding with the goal of avoiding re-victimized.
Participants will go through a 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm. After a washout period of 1 week, they will go through a 4 week period where clinicians will use a rehydration calculator application.
Gastric cancer is a heterogeneous and prevalent disease. The traditional environmental exposures associated with elevated risk of gastric cancer are less prevalent in the USA today. Genetic risks and risks associated with inflammation remain. Most cases are sporadic, and familial clustering is observed in about 10% of the cases. Hereditary gastric cancer accounts for a very low percentage of cases. Here we review the genetic and environmental risk factors associated with the disease. In addition, we will review screening guidelines and current modalities that are available for screening in high-risk populations.
Approximately 30 patients with advanced NSCLC will be enrolled. Patients will receive 3-week cycles of Cetuximab in combination with Carboplatin/Gemcitabine.
This invention provides a prodrug that help arthritis patients without increasing cardiovascular and gastrointestinal risk. A novel group of hybrid nitric oxide-releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs) , moiety attached via a one -carbon methylene spacer to the carboxylic acid group of the traditional NSAIDs aspirin, ibuprofen and indomethacin were synthesized. The ester prodrugs showed equipotent anti¬ inflammatory activities in vivo to that of the parent aspirin, ibuprofen and indomethacin.  The simultaneous release of parent drug and nitric oxide from the NO- prodrugs constitutes a potentially beneficial property for the prophylactic prevention of thrombus formation and adverse cardiovascular events such as stroke and myocardial infarction. Data acquired in an in vivo ulcer index (UI) assay showed that this group of ester prodrugs in which no lesions were observed when compared to the parent drugs at equivalent doses. Accordingly, these hybrid NO-NSAID prodrugs possessing a diazen-l-ium-1, 2-diolate moiety, represents a new approach for the rational design of anti- inflammatory drugs with reduced gastric ulcerogenicity .
Selenium is an essential nutrient. Selenium carries out its biological functions through selenoproteins. The most abundant selenoprotein in the plasma is selenoprotein P, which is largely synthesized in the liver. Patients with liver disease often have less than half the selenoprotein P levels of normal individuals. This suggests that people with liver disease are not meeting their selenium requirements and may benefit from additional selenium.

We proposed to compare the effects of two different forms of supplemental selenium on plasma selenium levels among patients with severe liver cirrhosis and healthy individuals (controls). Patients and controls were randomly assigned to one of 3 treatment groups: 200 µg selenium per day as selenate, 200 µg selenium per day as selenomethionine, or a placebo. The intervention lasted 8 weeks. Blood was measured initially and after 2 and 4 weeks of supplementation. Selenium, selenoprotein P and glutathione peroxidase were measured in the plasma. We compared changes in selenium and selenoprotein levels between liver cirrhosis patients and healthy controls.
Paliperidone palmitate Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
Participation will last approximately 6 months. Participants enrolled in the Usual Care arm will complete 3 questionnaires and collection of the HbA1c at the end of study.
A patch panel assembly is provided including an angle module having one or more RJ modules, one or more insulation displacement contact (IDC) module and a printed circuit board. Each of the RJ modules includes a base, an RJ plug receiving opening and spring contacts extending from the base into the RJ plug receiving opening. The IDC modules each include IDC housing with an IDC module base and insulation displacement contacts (IDCs) with IDC contact pins extending from the IDC module base. The printed circuit board has RJ contact holes receiving the spring contacts with the RJ module mounted to the printed circuit board and has IDC contact holes receiving IDC contact pins with the IDC module mounted to the printed circuit board as well as circuit traces connecting the RJ contact holes to the IDC contact holes. The plug receiving openings each have a plug insertion opening at an angle to the printed circuit board between 0° and not equal to 90°. A front panel is provided including a front face with a plurality of RJ module openings. The angle module is connected to the frame with the one or more RJ modules extending through RJ module openings and with each the plug insertion opening at an angle to the front face between 0° and not equal to 90°.
PROBLEM TO BE SOLVED: To obtain a makeup cosmetic which makes best use of the advantages of the conventional defocus making, and can cover its disadvantages, e.g. insufficient covering power, by making the cosmetic include spherical particles and particles treated with a perfluoroalkyl. SOLUTION: This cosmetic contains (A) spherical particles, which may be optionally surfacetreated and (B) particles treated with a perfluoroalkyl. The preferable examples of the component A include particles of nylon, silica and acrylic resin which may optionally have a hollow structure. The component A may be surface-treated with silicone, metal soap or the like. The component B is treated with alkyl trialkoxysilane or the like, to chemically modify the particle surfaces to have an alkyl group of perfluoroalkyl structure. The cosmetic contains the component A preferably at 10 to 90 wt.%, and component B at 0.1 to 50 wt.%.
Low-frequency repetitive transcranial magnetic stimulation (rTMS) has emerged as an effective intervention for alleviating symptoms of psychiatric disorders, particularly schizophrenia characterized by persistent auditory verbal hallucinations (AVH). However, the underlying mechanism of its action remain elusive. This study employed a randomized controlled design to investigate the impact of low-frequency rTMS on the neural connectivity at the stimulate site, specifically left temporoparietal junction (TPJ), in schizophrenia patients with suffering from AVH. Using Dynamic Causal Modeling (DCM), this study assessed changes in directed connectivity patterns and their correlations with clinical symptomatology. The results demonstrated significant improvements in AVH. Notably, significant changes in connectivity were observed, including both abnormal functional connectivity and effective connectivity among multiple brain regions. Particularly, the inhibition effects from the left precentral gyrus and left medial superior frontal gyrus to the left TPJ were closely associated with improvements in AVH. These findings underscore the potential of rTMS to effectively modulate neural pathways implicated in hallucinations in schizophrenia, thereby providing a neurobiological foundation for its therapeutic effects.
A system for testing and diagnosis of a medical condition includes a test device located at a test location and configured to perform a medical testing protocol for generating test data, and a recipient computer for receiving the patient data from the test device. The test device includes a computer and memory module for storing a patient record containing test data and a communications module for sending the patient record to a medical specialist. The test data comprises vascular test data. The recipient computer displays the test data to the medical specialist at a diagnosis center located remote from the test location. The recipient computer includes an input device configured to enter input indicative of a diagnosis by the medical specialist as a function of medical analysis of the test data. The input indicative of the diagnosis includes an electronic signature executed by the medical specialist.
Participants received no treatment for 3 months during the Control Period. They either exited the study at Month 3 or received an optional treatment with JUVÉDERM® VOLUMA® XC injectable gel treatment in both temples during the Post-Control Period and an optional touch-up treatment 30 days later. Participants did not receive any treatment during the Maintenance Treatment Period.
Cardiac arrhythmias have been observed in patients receiving MultiHance in clinical trials [see Adverse Reactions (6.1)]. Assess patients for underlying conditions or medications that predispose to arrhythmias.

A double-blind, placebo-controlled, 24-hour post dose continuous monitoring, crossover study in 47 subjects evaluated the effect of 0.2 mmol/kg MultiHance on ECG intervals, including QTc. The average changes in QTc values compared with placebo were minimal (<5 msec). QTc prolongation between 30 and 60 msec were noted in 20 subjects who received MultiHance vs. 11 subjects who received placebo. Prolongations ≥61 msec were noted in 6 subjects who received MultiHance and in 3 subjects who received placebo. None of these subjects had associated malignant arrhythmias. The effects on QTc by MultiHance dose, other drugs, and medical conditions were not systematically studied.
Daily oral dosing of neonatal/juvenile rats with valsartan at doses as low as 1 mg/kg/day (about 10% of the maximum recommended pediatric dose on a mg/m2 basis) from postnatal day 7 to postnatal day 70 produced persistent, irreversible kidney damage. These kidney effects in neonatal rats represent expected exaggerated pharmacological effects that are observed if rats are treated during the first 13 days of life. This period coincides with 36 weeks of gestation in humans, which could occasionally extend up to 44 weeks after conception in humans. In humans, nephrogenesis is thought to be complete around birth; however, maturation of other aspects of kidney function (such as glomerular filtration and tubular function) may continue until approximately 2 years of age. It is unknown whether post-natal use of valsartan before maturation of renal function is complete has long-term deleterious effects on the kidney.  [See Use in Specific Populations (8.4)] .
Poor and intermediate CYP2D6 metabolizers will be randomized to either low-dose-titration condition or treatment-as-usual condition. In the low-dose-titration condition, patients will be treated with risperidone 0.5mg bid for 5 days, then 1mg bid for 5 days, which may be increased to 1.5mg bid for another 5 days.
Delayed anaphylaxis after ingestion of red meat because of galactose-alpha-1,3-galactose (alpha-gal) syndrome has increased in recent years. The mechanism involves an immunoglobulin E reaction to alpha-gal, a molecule found in mammalian meat, dairy products, medications and excipients containing mammalian-derived components, and tick salivary glycans. Sensitization occurs due to the bite of a lone star tick and the transmission of alpha-gal molecules into person's bloodstream. We describe a case of alpha-gal syndrome with severe food, drug, and perioperative allergy in which anaphylaxis with hypovolemic shock occurred immediately after an emergency surgical procedure, when a gelatin-containing drug was injected. This case study confirms that the clinical manifestations of alpha-gal syndrome could be different depending on the route of administration, with immediate reactions if an alpha-gal-containing drug is injected and delayed type allergic manifestations occurring several hours after oral intake. The purpose of this report is to highlight the importance of risk communication in case of exposure to medical products and surgical procedures of patients with alpha-gal syndrome and to encourage drug manufacturers to indicate clearly the origin of excipients in product literature.
The invention discloses a medicine application of iron liposome. By taking animals with chronic inflammation as a model, a brand-new medicine which treats anaemia caused by the dysfunction of the iron absorption of the small intestine to relevant protein molecules and takes the iron liposome as an effective component is provided. The invention takes white rats with inflammatory anaemia as a model, adopts an oral stomach infusion method and compares the curative effect of the iron liposome for the anaemia with that of a chalybeate which is not enveloped by the liposome, and the iron liposome can obviously enhance the levels of the hemoglobin, the blood cell volume, the serum iron and the saturation rate of the transferrin of an organism in a short time, can act as a very good curative effect to the inflammatory anaemia and can not cause injuries to the health of the organism. The iron liposome is obviously superior to the traditional iron-replenished preparation. The invention can be used for treating the anaemia caused by the dysfunction of the iron absorption of the small intestine to the protein molecules because of various known or unknown reasons. Various tablets, capsules, dripping pills, oral liquid and food additives which are taken orally and contain the iron liposome are prepared.
Trileptal levels may decrease during pregnancy [see Warnings and Precautions (5.10)].

Pregnancy Category C

There are no adequate and well-controlled clinical studies of Trileptal in pregnant women; however, Trileptal is closely related structurally to carbamazepine, which is considered to be teratogenic in humans. Given this fact, and the results of the animal studies described, it is likely that Trileptal is a human teratogen. Trileptal should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Increased incidences of fetal structural abnormalities and other manifestations of developmental toxicity (embryolethality, growth retardation) were observed in the offspring of animals treated with either oxcarbazepine or its active 10-hydroxy metabolite (MHD) during pregnancy at doses similar to the maximum recommended human dose.

When pregnant rats were given oxcarbazepine (30, 300, or 1000 mg/kg) orally throughout the period of organogenesis, increased incidences of fetal malformations (craniofacial, cardiovascular, and skeletal) and variations were observed at the intermediate and high doses (approximately 1.2 and 4 times, respectively, the maximum recommended human dose [MRHD] on a mg/m2 basis). Increased embryofetal death and decreased fetal body weights were seen at the high dose. Doses ≥300 mg/kg were also maternally toxic (decreased body weight gain, clinical signs), but there is no evidence to suggest that teratogenicity was secondary to the maternal effects.

In a study in which pregnant rabbits were orally administered MHD (20, 100, or 200 mg/kg) during organogenesis, embryofetal mortality was increased at the highest dose (1.5 times the MRHD on a mg/m2 basis). This dose produced only minimal maternal toxicity.

In a study in which female rats were dosed orally with oxcarbazepine (25, 50, or 150 mg/kg) during the latter part of gestation and throughout the lactation period, a persistent reduction in body weights and altered behavior (decreased activity) were observed in offspring exposed to the highest dose (0.6 times the MRHD on a mg/m2 basis). Oral administration of MHD (25, 75, or 250 mg/kg) to rats during gestation and lactation resulted in a persistent reduction in offspring weights at the highest dose (equivalent to the MRHD on a mg/m2 basis).

To provide information regarding the effects of in utero exposure to Trileptal, physicians are advised to recommend that pregnant patients taking Trileptal enroll in the NAAED Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/.
PURPOSE:To produce the composite which is excellent in biological affinity and large in crushing resistance by mixing calcium hydrogen phosphate with calcium carbonate so that Ca and P are regulated to a specified molar ratio, pressurizing and molding the mixture and calcining the molded body in the specified conditions. CONSTITUTION:Ca source (calcium carbonate) and P source (calcium hydrogen phosphate) are mixed so that the molar ratio (Ca/P) of Ca and P is regulated to a range exceeding 1.77 and less than 2.00. The mixture is perssurized and molded. At this time, the particle diameter of a raw material is regulated to about 1-5mum and the pressing pressure is regulated to about 0.1-2.0t/cm<2>. Then this mixture is calcined at 1250-1600 deg.C for one hour or more and allowed to react and cooled. When it is cooled to about 1200 deg.C, it is maintained for about one hour and thereafter quenched at room temp. Thereby a tetracalcium phosphate composite contg. hydroxy-apatite excellent in biological affinity and crushing resistance. is obtained. This is preferable as medical application incorporating dental material.